Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. Clegg NJ, et al. Among authors: jung me. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. Cancer Res. 2012. PMID: 22266222 Free PMC article.
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Tran C, et al. Among authors: jung me. Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9. Science. 2009. PMID: 19359544 Free PMC article. Clinical Trial.
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.
Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, Jung ME, Huang J, Wu L. Escamilla J, et al. Among authors: jung me. Cancer Res. 2015 Mar 15;75(6):950-62. doi: 10.1158/0008-5472.CAN-14-0992. Epub 2015 Mar 3. Cancer Res. 2015. PMID: 25736687 Free PMC article.
An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity.
Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN, Komisopoulou E, Henkin AH, Soto H, Chamberlain BT, Vergnes L, Jung ME, Torres JZ, Liau LM, Christofk HR, Prins RM, Mischel PS, Reue K, Graeber TG, Bensinger SJ. Williams KJ, et al. Among authors: jung me. Cancer Res. 2013 May 1;73(9):2850-62. doi: 10.1158/0008-5472.CAN-13-0382-T. Epub 2013 Feb 25. Cancer Res. 2013. PMID: 23440422 Free PMC article.
Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.
Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A. Shi Y, et al. Among authors: jung me. Cancer Res. 2016 Oct 1;76(19):5822-5831. doi: 10.1158/0008-5472.CAN-16-1019. Epub 2016 Aug 16. Cancer Res. 2016. PMID: 27530328 Free PMC article.
Development and preclinical pharmacology of a novel dCK inhibitor, DI-87.
Poddar S, Capparelli EV, Rosser EW, Gipson RM, Wei L, Le T, Jung ME, Radu C, Nikanjam M. Poddar S, et al. Among authors: jung me. Biochem Pharmacol. 2020 Feb;172:113742. doi: 10.1016/j.bcp.2019.113742. Epub 2019 Dec 6. Biochem Pharmacol. 2020. PMID: 31812677 Free PMC article.
332 results